Equilibrium between host and cancer caused by effector T cells killing tumor stroma.

The growth of solid tumors depends on tumor stroma. A single adoptive transfer of CD8(+) CTLs that recognize tumor antigen-loaded stromal cells, but not the cancer cells because of MHC restriction, caused long-term inhibition of tumor growth. T cells persisted and continuously destroyed CD11b(+) myeloid-derived, F4/80(+) or Gr1(+) stromal cells during homeostasis between host and cancer. Using high-affinity T-cell receptor tetramers, we found that both subpopulations of stromal cells captured tumor antigen from surrounding cancer cells. Epitopes on the captured antigen made these cells targets for antigen-specific T cells. These myeloid stromal cells are immunosuppressive, proangiogenic, and phagocytic. Elimination of these myeloid cells allowed T cells to remain active, prevented neovascularization, and prevented tumor resorption so that tumor size remained stationary. These findings show the effectiveness of adoptive CTL therapy directed against tumor stroma and open a new avenue for cancer treatments.

[1]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[2]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[3]  C. Eng,et al.  Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. , 2007, JAMA.

[4]  R. Weichselbaum,et al.  Induced sensitization of tumor stroma leads to eradication of established cancer by T cells , 2007, The Journal of experimental medicine.

[5]  Claudio Campa,et al.  Targeting VEGF-A to treat cancer and age-related macular degeneration. , 2007, Annual review of medicine.

[6]  J. Califano,et al.  Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.

[7]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[8]  A. Jubb,et al.  Predicting benefit from anti-angiogenic agents in malignancy , 2006, Nature Reviews Cancer.

[9]  C. Liu,et al.  Targeting tumor-associated macrophages as a novel strategy against breast cancer. , 2006, The Journal of clinical investigation.

[10]  M. Loeffler,et al.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.

[11]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[12]  H. Schreiber,et al.  The role of stroma in immune recognition and destruction of well-established solid tumors. , 2006, Current opinion in immunology.

[13]  D. Gabrilovich,et al.  Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer , 2006, Cancer Immunology, Immunotherapy.

[14]  P. Rodriguez,et al.  T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. , 2006, Seminars in cancer biology.

[15]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[16]  Y. Numata,et al.  Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas , 2005, Gut.

[17]  D. Gabrilovich,et al.  Tumor Associated CD8+ T-Cell Tolerance Induced by Bone Marrow Derived Immature Myeloid Cells , 2005 .

[18]  A. Mantovani,et al.  Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. , 2005, Cancer research.

[19]  S. Dubinett,et al.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma , 2005, The Journal of experimental medicine.

[20]  D. Gabrilovich,et al.  Tumor-Associated CD8+ T Cell Tolerance Induced by Bone Marrow-Derived Immature Myeloid Cells1 , 2005, The Journal of Immunology.

[21]  K. Maruyama,et al.  Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. , 2005, The Journal of clinical investigation.

[22]  Jun Yao,et al.  Distinct epigenetic changes in the stromal cells of breast cancers , 2005, Nature Genetics.

[23]  D. Gabrilovich,et al.  STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion1 , 2005, The Journal of Immunology.

[24]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[25]  T. Blankenstein.  The role of tumor stroma in the interaction between tumor and immune system. , 2005, Current opinion in immunology.

[26]  D. Gabrilovich.  Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.

[27]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[28]  A. Houghton,et al.  FAPα, a surface peptidase expressed during wound healing, is a tumor suppressor , 2004, Oncogene.

[29]  H. Schreiber,et al.  Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.

[30]  Qingsheng Li,et al.  Role of Immature Myeloid Gr-1+ Cells in the Development of Antitumor Immunity , 2004, Cancer Research.

[31]  J. Berzofsky,et al.  Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance , 2003, The Journal of Experimental Medicine.

[32]  J. Bubeník.  Tumour MHC class I downregulation and immunotherapy (Review). , 2003, Oncology reports.

[33]  Tsutomu Yoshida,et al.  Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma , 2003, British Journal of Cancer.

[34]  Bin Yu,et al.  All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.

[35]  M. Dewhirst,et al.  Synergy between tumor immunotherapy and antiangiogenic therapy. , 2003, Blood.

[36]  J. Blattman,et al.  Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. , 2003, Cancer cell.

[37]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[38]  R. Mulligan,et al.  Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Blankenstein,et al.  Tumor Rejection by Disturbing Tumor Stroma Cell Interactions , 2001, The Journal of experimental medicine.

[40]  A. Wellmann,et al.  Presence of genetic alterations in microdissected stroma of human colon and breast cancers. , 2001, Journal of molecular medicine.

[41]  R. Ronca,et al.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. , 2000, Blood.

[42]  A. Akeson,et al.  Embryonic vasculogenesis by endothelial precursor cells derived from lung mesenchyme , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[43]  S Ferrone,et al.  HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. , 1999, Molecular medicine today.

[44]  S. Rosenberg,et al.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. , 1998, Journal of immunology.

[45]  H. Schreiber,et al.  Antigenic cancer cells that escape immune destruction are stimulated by host cells. , 1995, Cancer research.

[46]  H. Schreiber,et al.  Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  H. Schreiber,et al.  Inhibition of tumor growth by elimination of granulocytes , 1995, The Journal of experimental medicine.

[48]  H. Schreiber,et al.  Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells , 1992, The Journal of experimental medicine.

[49]  F. Garrido,et al.  Role of altered expression of HLA class I molecules in cancer progression. , 2007, Advances in experimental medicine and biology.

[50]  H. Schreiber,et al.  Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. , 2005, Cancer immunity.